DOP2012000032A - DERIVADOS DE AMIDAS ESPIROCÍCLICAS QUE POSSEN ACTIVIDAD EN LOS RECEPTORES MUSCARINICOS Y RECPETORES ß2 - Google Patents
DERIVADOS DE AMIDAS ESPIROCÍCLICAS QUE POSSEN ACTIVIDAD EN LOS RECEPTORES MUSCARINICOS Y RECPETORES ß2Info
- Publication number
- DOP2012000032A DOP2012000032A DO2012000032A DO2012000032A DOP2012000032A DO P2012000032 A DOP2012000032 A DO P2012000032A DO 2012000032 A DO2012000032 A DO 2012000032A DO 2012000032 A DO2012000032 A DO 2012000032A DO P2012000032 A DOP2012000032 A DO P2012000032A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- receivers
- spirocyclic
- muscarinic
- activity
- derivatives
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 230000003551 muscarinic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 (4- (2-ethylthiazol-4-carbonyl) -1-oxa-4,9-diazaspiro [5.5] undecan-9-yl) methyl Chemical group 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 abstract 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Derivados amida espirocíclicos que poseen actividad en los receptores muscarínicos y receptores ß2 , donde ArCH2CH2NH- representa un grupo de unión ß-adrenoceptor, procesos para su preparación, composiciones farmacéuticas que los contienen, un proceso para preparar dichas composiciones farmacéuticas, su uso en terapia, e intermediarios para uso en su preparación destinadas para el tratamiento de enfermedades tales como, sin limitacion alguna, diversos trastornos pulmonares como la enfermedad pulmonar obstructiva cronica (EPOC) y el asma. Por ejemplo, Ditrifluoroacetato de 3-(2-cloro-3-((4-(2-etiltiazol-4-carbonil)-1-oxa-4,9-diazaspiro[5,5]undecan-9-il)metil)fenetoxi)-N-ciclopentil-N-(2-(2-(5-hidroxi-3-oxo-3,4-dihidro-2H-benzo[b][1,4]oxazin-8-il)etilamino)etil)propanamida
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0913342.2A GB0913342D0 (en) | 2009-07-31 | 2009-07-31 | Compounds - 801 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000032A true DOP2012000032A (es) | 2017-08-15 |
Family
ID=41129405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000032A DOP2012000032A (es) | 2009-07-31 | 2012-01-31 | DERIVADOS DE AMIDAS ESPIROCÍCLICAS QUE POSSEN ACTIVIDAD EN LOS RECEPTORES MUSCARINICOS Y RECPETORES ß2 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8455483B2 (es) |
| EP (1) | EP2459572B1 (es) |
| JP (1) | JP5612092B2 (es) |
| KR (1) | KR101664525B1 (es) |
| CN (1) | CN102625808B (es) |
| AR (1) | AR080601A1 (es) |
| AU (1) | AU2010277384B2 (es) |
| BR (1) | BR112012008043A2 (es) |
| CA (1) | CA2768527C (es) |
| CL (1) | CL2012000263A1 (es) |
| CO (1) | CO6491034A2 (es) |
| CR (1) | CR20120054A (es) |
| CU (1) | CU24103B1 (es) |
| DO (1) | DOP2012000032A (es) |
| EA (1) | EA020566B1 (es) |
| ES (1) | ES2702467T3 (es) |
| GB (1) | GB0913342D0 (es) |
| GT (1) | GT201200028A (es) |
| HN (1) | HN2012000217A (es) |
| IL (1) | IL217557A (es) |
| MX (1) | MX2012001232A (es) |
| MY (1) | MY163117A (es) |
| NI (1) | NI201200018A (es) |
| NZ (1) | NZ597589A (es) |
| PE (1) | PE20121441A1 (es) |
| SA (1) | SA110310628B1 (es) |
| SG (1) | SG177634A1 (es) |
| TR (1) | TR201819140T4 (es) |
| TW (1) | TWI443103B (es) |
| UA (1) | UA106887C2 (es) |
| UY (1) | UY32814A (es) |
| WO (1) | WO2011012896A2 (es) |
| ZA (1) | ZA201201473B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101273200B1 (ko) | 2008-02-06 | 2013-06-17 | 펄마젠 쎄라퓨틱스 (시너지) 리미티드 | 화합물 |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| GB201021992D0 (en) * | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) * | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| WO2016179349A1 (en) * | 2015-05-05 | 2016-11-10 | Northwestern University | Cxcr4 chemokine receptor modulators |
| WO2018059537A1 (zh) * | 2016-09-30 | 2018-04-05 | 四川海思科制药有限公司 | 一种二氮杂螺[5.5]十一碳烷衍生物及其用途 |
| JP6963616B2 (ja) | 2016-12-14 | 2021-11-10 | ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド | ４級アンモニウム塩構造を有する二官能性化合物 |
| CN110678463B (zh) | 2017-06-01 | 2023-06-06 | 百时美施贵宝公司 | 经取代的含氮化合物 |
| EP3682906A1 (en) * | 2019-01-17 | 2020-07-22 | Julius-Maximilians-Universität Würzburg | Compound targeting norepinephrine transporter |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2707186A (en) | 1954-05-06 | 1955-04-26 | Hoffmann La Roche | Imidazolone derivatives |
| AU565621B2 (en) | 1983-04-26 | 1987-09-24 | Smithkline Beckman Corporation | Dopaminergic carbostyrils |
| FR2665440B1 (fr) | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| GB9604578D0 (en) | 1996-03-04 | 1996-05-01 | Sericol Ltd | Photocurable compositions |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| ES2329586T3 (es) * | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| JP4846709B2 (ja) | 2004-03-10 | 2011-12-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ５員複素環で置換されているｍｔｐ阻害性アリールピペリジン若しくはピペラジン |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| US20050215542A1 (en) | 2004-03-23 | 2005-09-29 | Pfizer Inc | Compounds for the treatment of diseases |
| DE102004024453A1 (de) * | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP2008516939A (ja) | 2004-10-15 | 2008-05-22 | アストラゼネカ アクチボラグ | 化学化合物 |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| EP1961744B1 (en) * | 2005-11-18 | 2013-04-17 | Ono Pharmaceutical Co., Ltd. | Basic group-containing compound and use thereof |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| AU2007284548A1 (en) * | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| US20100056508A1 (en) * | 2006-12-20 | 2010-03-04 | Astrazeneca Ab | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
| GB0702413D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| GB0702459D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 669 |
| KR101273200B1 (ko) * | 2008-02-06 | 2013-06-17 | 펄마젠 쎄라퓨틱스 (시너지) 리미티드 | 화합물 |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
-
2009
- 2009-07-31 GB GBGB0913342.2A patent/GB0913342D0/en not_active Ceased
-
2010
- 2010-07-29 AU AU2010277384A patent/AU2010277384B2/en not_active Ceased
- 2010-07-29 ES ES10752118T patent/ES2702467T3/es active Active
- 2010-07-29 JP JP2012522254A patent/JP5612092B2/ja not_active Expired - Fee Related
- 2010-07-29 CU CU2012000021A patent/CU24103B1/es active IP Right Grant
- 2010-07-29 KR KR1020127005165A patent/KR101664525B1/ko not_active Expired - Fee Related
- 2010-07-29 BR BR112012008043-1A patent/BR112012008043A2/pt not_active Application Discontinuation
- 2010-07-29 CN CN201080043822.8A patent/CN102625808B/zh not_active Expired - Fee Related
- 2010-07-29 NZ NZ597589A patent/NZ597589A/en not_active IP Right Cessation
- 2010-07-29 MX MX2012001232A patent/MX2012001232A/es active IP Right Grant
- 2010-07-29 PE PE2012000138A patent/PE20121441A1/es active IP Right Grant
- 2010-07-29 UA UAA201200405A patent/UA106887C2/uk unknown
- 2010-07-29 TR TR2018/19140T patent/TR201819140T4/tr unknown
- 2010-07-29 SG SG2012002358A patent/SG177634A1/en unknown
- 2010-07-29 EA EA201290077A patent/EA020566B1/ru not_active IP Right Cessation
- 2010-07-29 WO PCT/GB2010/051242 patent/WO2011012896A2/en not_active Ceased
- 2010-07-29 MY MYPI2012000429A patent/MY163117A/en unknown
- 2010-07-29 EP EP10752118.9A patent/EP2459572B1/en active Active
- 2010-07-29 CA CA2768527A patent/CA2768527C/en not_active Expired - Fee Related
- 2010-07-30 AR ARP100102795A patent/AR080601A1/es active IP Right Grant
- 2010-07-30 US US12/847,000 patent/US8455483B2/en not_active Expired - Fee Related
- 2010-07-30 UY UY0001032814A patent/UY32814A/es not_active Application Discontinuation
- 2010-07-30 TW TW099125331A patent/TWI443103B/zh not_active IP Right Cessation
- 2010-07-31 SA SA110310628A patent/SA110310628B1/ar unknown
-
2012
- 2012-01-12 CO CO12004253A patent/CO6491034A2/es active IP Right Grant
- 2012-01-16 IL IL217557A patent/IL217557A/en active IP Right Grant
- 2012-01-31 HN HN2012000217A patent/HN2012000217A/es unknown
- 2012-01-31 GT GT201200028A patent/GT201200028A/es unknown
- 2012-01-31 DO DO2012000032A patent/DOP2012000032A/es unknown
- 2012-01-31 CL CL2012000263A patent/CL2012000263A1/es unknown
- 2012-01-31 CR CR20120054A patent/CR20120054A/es unknown
- 2012-01-31 NI NI201200018A patent/NI201200018A/es unknown
- 2012-02-28 ZA ZA2012/01473A patent/ZA201201473B/en unknown
- 2012-09-14 US US13/617,978 patent/US8476265B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002099A1 (es) | Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma. | |
| CL2007003742A1 (es) | Compuestos derivados heterociclicos, inhibidores de protein quinasas activadas por mitogenos; proceso de preparacion; composicion farmaceutica; articulo de manufactura; y uso para el tratamiento de enfermedades tales como trastornos hiperproliferativ | |
| CL2007002272A1 (es) | Compuestos derivados de n-metil-c-normorfinano; composicion farmaceutica; y uso para la reduccion de efectos secundarios del tratamiento de opioides tales como constipacion y nauseas, y para tratar trastornos mediados por la actividad de receptores o | |
| CL2008000180A1 (es) | Sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)fenil]ciclobutanocarboxamida; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como depresion, trastornos del sueno, ansiedad y enfermedades del tracto | |
| CL2007002163A1 (es) | Compuestos derivados de 2-fenilindol, antagonistas del receptor de prostaglandina d2; composicion farmaceutica; y uso para tratar enfermedades alergicas tales como asma bronquial y rinitis alergica, broncoconstriccion, epoc, accidente cerebrovascular | |
| ECSP11011276A (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma. | |
| CL2007002859A1 (es) | Compuestos derivados de pirazol, moduladores del receptor 5-ht2a; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento de arteriopatia coronaria, infarto miocardico, angina, trastorno del sueno, asma, reduci | |
| CL2012000185A1 (es) | Compuestos derivados de oxazina o oxazepina, inhibidores de bace; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del deterioro cognitivo, neuropatia amiloide, o enfermedad de alzheimer. | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| NI201100026A (es) | Nuevos derivados de sulfamida sustituidos | |
| BR112014007721A2 (pt) | processos para preparar compostos úteis como inibidores de atr quinase | |
| BR112013013167A8 (pt) | inibidores de bromodomínio e usos dos mesmos | |
| AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
| CL2008003577A1 (es) | Compuestos derivados de imidazo[1,5-a] pirido[3,2-e]pirazina, 2, 6, 7, 9 tetrasustituidos; inhibidores de fosfodiesterasa 10; procedimiento de preparación; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar enfermedades relacionadas con el sistema nervioso central, obesidad y trastornos del metabolismo. | |
| CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
| BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
| CL2012003212A1 (es) | Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson. | |
| SMT201200017B (it) | Nuovi antagonisti P2X7R e il loro uso. | |
| CL2015000096A1 (es) | Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros | |
| BRPI0915428A2 (pt) | derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios | |
| UY31922A (es) | Compuestos | |
| CO6491034A2 (es) | Derivados de amida espirocíclicos | |
| MX383762B (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| BRPI1012205A2 (pt) | compostos com duas porções heteroarila bicíclica fundidas como moduladores de leucotrieno a4 hidrolase | |
| CL2007002768A1 (es) | Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki |